USPTO Examiner ZHU JIANJIAN - Art Unit 1631

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18672796Targeting Nrip1 to Alleviate Metabolic DiseaseMay 2024May 2025Allow1101YesNo
18424664METHOD FOR GENERATING T CELL LINEAGE POPULATIONS FROM STEM/PROGENITOR CELLSJanuary 2024February 2025Allow1311YesNo
18411991PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPYJanuary 2024February 2025Allow1320YesNo
18410900PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPYJanuary 2024October 2024Allow920YesNo
18178849CAR T CELL THERAPIES WITH ENHANCED EFFICACYMarch 2023December 2024Abandon2101NoNo
17748997IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATUREMay 2022March 2024Abandon2101NoNo
17744266ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLSMay 2022April 2025Allow3521YesNo
17662629TARGETING WNT SIGNALING FOR IMPROVED GLIOMA IMMUNOTHERAPYMay 2022November 2024Abandon3121NoNo
17659432SYSTEM, DEVICE, AND METHOD FOR CELL CRYOPRESERVATION VIA SAND-MEDIATED ICE SEEDINGApril 2022May 2025Allow3731YesNo
17680379HUMANIZED MOUSE MODELS OF THE FCRN RECYCLING PATHWAYFebruary 2022July 2024Allow2911NoNo
17646398METHOD FOR CULTURING CELLS INTO WHICH REPROGRAMMING FACTOR IS INTRODUCEDDecember 2021October 2024Allow3421YesNo
17553391PROSTATE CANCER CHIMERIC ANTIGEN RECEPTORSDecember 2021March 2024Allow2711YesNo
17541917MULTICISTRONIC MIRNA DELIVERY FOR CARDIAC REPROGRAMMINGDecember 2021March 2025Allow3931YesNo
17530855METHOD OF PRODUCING PLACENTA-LIKE ORGANOID, PLACENTA-LIKE ORGANOID, AND PRODUCTION OR TEST KITNovember 2021October 2023Abandon2301NoNo
17605510HIGH DENSITY LIPOPROTEIN NANOPARTICLES AND RNA TEMPLATED LIPOPROTEIN PARTICLES FOR OCULAR THERAPYOctober 2021May 2025Abandon4301NoNo
17504317Mercury Controlled Gene ExpressionOctober 2021November 2024Abandon3711NoNo
17498158Platform Oncolytic Vector for Systemic DeliveryOctober 2021April 2025Allow4231YesNo
17497367Targeting Nrip1 to Alleviate Metabolic DiseaseOctober 2021February 2024Allow2921YesNo
17601384MODIFIED IMMUNE RECEPTOR CONSTRUCTSOctober 2021May 2025Abandon4301NoNo
17480473ENGINEERED IMMUNE CELLS WITH DOMINANT SIGNALSSeptember 2021September 2024Allow3630YesNo
17474535RECOMBINANT ADENO ASSOCIATED VIRUS ENCODING CLARIN-1 AND USES THEREOFSeptember 2021June 2024Allow3330YesNo
17438380HIGH AVIDITY WT1 T CELL RECEPTORS AND USES THEREOFSeptember 2021June 2025Allow4511YesNo
17380214CELL CULTURE SCAFFOLD MATERIAL, RESIN FILM, CELL CULTURE VESSEL, AND METHOD FOR CULTURING A CELLJuly 2021February 2025Abandon4331YesNo
17377830LENTIVIRUS PACKAGING SYSTEM, LENTIVIRUS PRODUCED BY THE SAME, CELL TRANSDUCED BY THE LENTIVIRUS, METHOD FOR IMPROVING LENTIVIRUS PRODUCTION IN A HOST CELL, AND METHOD OF USING THE CELL FOR TREATING CANCERJuly 2021March 2024Allow3221YesNo
17374157MICROCARRIERS WITH SCAFFOLD STRUCTURE AND CONTINUOUS OUTER WALL FOR CULTURING CELLSJuly 2021March 2024Abandon3221NoNo
17415239A PHYSIOLOGICAL BIOMIMETIC CULTURE SYSTEM FOR HEART SLICESJune 2021August 2024Allow3821YesNo
17326661Novel T-Cell Receptor and LigandMay 2021May 2024Abandon3621NoNo
17290708PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPYApril 2021June 2025Allow5011YesNo
17236726METHODS AND MATERIALS FOR TREATING OSTEOARTHRITISApril 2021December 2023Abandon3220NoNo
17224909Treatment of Acute Respiratory Distress Syndrome by T Regulatory CellsApril 2021February 2024Abandon3411NoNo
17270943THERAPEUTIC AGENTS COMPRISING NUCLEIC ACIDS AND TCR MODIFIED IMMUNE CELLS AND USES THEREOFFebruary 2021September 2023Allow3121YesNo
17264485METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLSJanuary 2021December 2024Abandon4621NoNo
17152136CANCER TARGETS AND USES THEREOFJanuary 2021March 2025Abandon5021NoNo
17248071LIVESTOCK ANIMALS WITH IMPROVED GROWTH PERFORMANCEJanuary 2021June 2023Allow2911YesNo
17251272IMMUNODEFICIENT MOUSEDecember 2020March 2025Allow5121YesNo
17057945METHODS FOR ISOLATING TUMOR-SPECIFIC IMMUNE CELLS FROM A SUBJECT FOR ADOPTIVE CELL THERAPY AND CANCER VACCINESNovember 2020February 2025Abandon5111NoNo
17051353NEURAL STEM CELL COMPOSITIONS INCLUDING CHIMERIC POXVIRUSES FOR CANCER TREATMENTOctober 2020January 2025Abandon5111NoNo
17050805CAR T CELL THERAPIES WITH ENHANCED EFFICACYOctober 2020May 2023Abandon3001NoNo
17080185GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMSOctober 2020January 2024Allow3820YesNo
17050045METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOFOctober 2020May 2025Allow5521YesNo
17078742PERFUSION PLATE FOR MICROARRAY 3D BIOPRINTINGOctober 2020July 2023Allow3311YesNo
17049956IMMATURE DENTAL PULP STEM CELLS AND METHODS OF USE TO TREAT BONE MARROW FAILUREOctober 2020November 2024Abandon4911NoNo
17074074MICRO-ENGINEERED MODELS OF THE HUMAN EYE AND METHODS OF USEOctober 2020February 2024Allow4020YesNo
17070368THREE DIMENSIONAL HYDROGEL FOR CULTURING OF CELLSOctober 2020April 2023Abandon3001NoNo
17028836METHODS FOR SCREENING GENETIC PERTURBATIONSSeptember 2020November 2023Allow3730YesNo
17025953COST EFFECTIVE CULTURE MEDIA AND PROTOCOL FOR HUMAN INDUCED PLURIPOTENT STEM CELLSSeptember 2020May 2025Abandon5631YesNo
17018728NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOFSeptember 2020April 2023Allow3110YesNo
16980359FOAMY VIRUSES AND METHODS OF USESeptember 2020October 2024Allow4911YesNo
17004080OPTIMIZED IN VITRO CELLULAR SYSTEM FOR BBB PERMEABILITY LINKED NEUROACTIVITY SCREENINGAugust 2020May 2023Abandon3210NoNo
16971971A CD19-BASED CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOFAugust 2020January 2025Allow5321YesNo
16968392FREE-STANDING, TRANSFERRABLE VASCULAR NETWORKS VIA GUIDED SELF-ASSEMBLY AND USE IN CELL REPLACEMENT THERAPIESAugust 2020December 2024Abandon5211NoNo
16988145METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO INTESTINAL EPITHELIAL CELLSAugust 2020May 2024Allow4520YesNo
16960529MIRNA MODULATION OF T CELL SIGNALING AND USES THEREOFJuly 2020June 2025Abandon5941NoNo
16956230DIGITALIZED HUMAN ORGANOIDS AND METHODS OF USING SAMEJune 2020February 2024Allow4311YesNo
16954349ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOFJune 2020April 2025Allow5841YesNo
16767931SHUTTLE PLASMID REPLICABLE IN CLOSTRIDIUM AND E. COLI AND RECOMBINANT MICROORGANISM PREPARED THEREWITH AND HAVING ENHANCED PENTOSE METABOLISM AND FERMENTATION PERFORMANCEMay 2020March 2025Abandon5721NoNo
15930947IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOFMay 2020June 2023Abandon3711NoNo
16759632EUKARYOTIC CELL LINEApril 2020February 2023Allow3411YesNo
16838709METHODS AND COMPOSITIONS FOR INSERTION OF ANTIBODY CODING SEQUENCES INTO A SAFE HARBOR LOCUSApril 2020October 2024Abandon5541NoNo
16649522METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLSMarch 2020August 2024Allow5221YesNo
16811672Systems and Methods for Automated Processing of Signals from Cardiomyocytes in an Unbiased MannerMarch 2020July 2023Abandon4110YesNo
16798465Therapeutic compositions and applications that comprise nucleic acids and adoptively transferred immune cellFebruary 2020August 2023Allow4121YesNo
16622800EXPRESSION VECTORS COMPRISING ENGINEERED GENESDecember 2019June 2023Allow4211YesNo
16607834GENE THERAPY FOR OCULAR DISORDERSOctober 2019August 2023Allow4621YesNo
16585286METHODS FOR INTEGRATION OF TRANSGENE DNASeptember 2019April 2023Abandon4201NoNo
16458326Inhibition of Fibrosis and AF By TGF-Beta Inhibition in the Posterior Left Atrium (PLA)July 2019March 2025Allow6021YesNo
16466265COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIESJune 2019November 2023Allow5341YesNo
15527685TKI PERMEABILITY ENHANCERSMay 2017May 2023Allow6061YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner ZHU, JIANJIAN - Prosecution Strategy Guide

Executive Summary

Examiner ZHU, JIANJIAN works in Art Unit 1631 and has examined 64 patent applications in our dataset. With an allowance rate of 56.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner ZHU, JIANJIAN's allowance rate of 56.2% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ZHU, JIANJIAN receive 1.75 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ZHU, JIANJIAN is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +88.3% benefit to allowance rate for applications examined by ZHU, JIANJIAN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.5% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.8% of cases where such amendments are filed. This entry rate is in the 48% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.